Research programme: human heavy chain antibodies - TeneoBio

Drug Profile

Research programme: human heavy chain antibodies - TeneoBio

Alternative Names: UniAbs™; UniDabs™

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TeneoBio
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Infections

Most Recent Events

  • 12 Jun 2017 TeneoBio in-licenses SUREtechnology Platform™ technology from Selexis
  • 16 Sep 2016 TeneoBio in-licenses OmniFlic® technology from Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top